Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis

Adverse Drug Reactions and Toxicological Reviews

Volumn 15, Issue 1, 1996, Pages 9-50

  Cribb, A E ^a   Lee, Belle L ^b   Trepanier, Lauren A ^c   Spielberg, S P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

Adverse drug reactions; Hypersensitivity; Pathogenesis; Sulphamethoxazole; Sulphonamide trimethoprim

Indexed keywords

SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM;

BLOOD DISEASE; DRUG HYPERSENSITIVITY; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATORY DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; REVIEW; SKIN MANIFESTATION;

ANTI-INFECTIVE AGENTS; DRUG COMBINATIONS; DRUG HYPERSENSITIVITY; HUMANS; SULFAMETHOXAZOLE; SULFAMOXOLE; SULFANILAMIDES; SULFONAMIDES; TRIMETHOPRIM;

EID: 0029988450     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (219)

1. Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. The Macmillan Company, New York; 1960: 1276-320.
2. Anonymous. Serious adverse reaction with sulfonamides. FDA Drug Bull 1984; 14: 5-6.
3. Gordin FM, Simon GL, Wofsby CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495-99.
4. Mandell GL, Sande MA. Sulfonamide, trimethoprim-sulfamethoxazole, and agents for urinary tract infections. In The Pharmacological Basis of Therapeutics, Gilman AG, Goodman LS, Rail TW, Murad R, eds. 1985; pp. 1095-114. Macmillan Publishing Co., New York.
5. Gutman LT. The use of trimethoprim-sulfamethoxazole in children: a review of adverse reactions and indications. Pediair Infect Dis J 1984; 3: 349-57.
6. Heimpel H, Raghavacher A. Hematological side effects of co-trimoxazole. Infection 1987; 15 suppl 5: S248-52.
7. Murphy JL, Griswold WR, Reznik VM, Mendoza SA. Trimethoprim/sulfamethoxazole-induced renal tubular acidosis. Child Nephrol Urol 1990; 10: 49-50.
8. Murphy JL. Renal tubular acidosis in children treated with trimethoprim-sulfamethoxazole during therapy for acute lymphoid leukemia. Pediatrics 1992; 89: 1072-74.
9. Stevens RC, Laizure SC, Williams CL, Stein DA. Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. Antimicrob Agents Chemother 1991; 35: 1884-90.
10. Bozzette SA, Forthal D, Sattler FR, Kemper C, Richman DD, Tilles JG, Leedom J, McCutchan JA. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. Am J Med 1995; 98: 177-82.
11. McKnight JT, Gaskins SE, Pieroni RE, Machen GM. Severe hypoglycemia associated with trimethoprim-sulfamethoxazole therapy. J Am Board Fam Pract 1988; 1: 143-5.
12. Johnson JA, Kappel JE, Sharif MN. Hypoglycemia secondary to trimethoprim/ sulfamethoxazole administration in a renal transplant patient. Ann Pharmacotherapy 1993; 27: 304-6.
13. MacKenzie CG, MacKenzie JB. Effect of sulphonamides and thioureas on the thyroid gland and basal metabolism. Endocrinol 1943; 32: 185-209.
14. Roepke RR, Maren TH, Mayer E. Experimental investigations of sulphamethoxypridazine. Ann N Y Acad Sci 1957; 69: 457-72.
15. Milne K, Greer MA. Clarification of the diverse actions of iodide on antithyroid effect of sulphonamides and thioureas. Proc Soc Exp Biol Med 1962; 109: 174-76.
16. Lagler VF, Kretzschmar R, Leuschner F, et al. Toxikologische untersuchungen der kombination sulphamoxol/trimethoprim (CN 3123), eines neuen breitbandchemo-therapeutikums. Arzneimittelforschung 1976; 26: 634-43.
17. Nishikawa S. Effects of sulphonamide on the pituitary-thyroid gland: morphological changes of thyroid gland and variation in plasma thyroxine and triiodothyronine. J Toxicol Sci 1983; 8: 47-59.
18. Fullerton FR, Kushmaul RJ, Suber RL, et al. Influence of oral administration of sulphamethazine on thyroid hormone levels in Fischer 344 rats. J Toxicol Environ Health 1987: 175-85.
19. Blackwell TE, Werdin RE, Eisenmenger MC et al. Goitrogenic effects in offspring of swine fed sulphadimethoxine and ormetoprim in late gestation. J Am Vet Med Assoc 1989; 194: 519-23.
20. Doerge DR, Decker CJ. Inhibition of peroxidase-catalyzed reactions by arylamines: mechanism for the anti-thyroid action of sulphamethazine. Chem Res Toxicol 1994; 7: 164-9.
21. Kobayashi R, Harada A, Kanno Y, et al. Potentiation of goitrogenic action of sulphonamide by trimethoprim. Proc Soc Exp Biol Med 1973; 142: 776-80.
22. Cohen HN, Fyffe JA, Ratcliffe WA, et al. Effects of trimethoprim and sulphonamide preparations on the pituitary-thyroid axis of rodents. J Endocrinol 1981; 91: 299-303.
23. Swarm RL, Roberts GKS, Levy AC et al. Observations on the thyroid gland in rats following the administration of sulphamethoxazole and trimethoprim. Toxicol Appl Pharmacol 1973; 24: 351-63.
24. Littlefield NA, Gaylor DW, Blackwell B-N, et al. Chronic toxicity/carcinogenicity studies of sulphamethazine in B6C3F1 mice. Food Chem Toxicol 1989; 27: 455-63.
25. Littlefield NA, Sheldon WG, Allen R, et al. Chronic toxicity/carcinogenicity studies of sulphamethazine in Fischer 344/N rats: two generation exposure. Food Chem Toxicol 1990; 28: 157-67.
26. Heath JE, Littlefield NA. Morphological effects of subchronic oral sulphamethazine administration on Fischer 344 rats and B6C3F1 mice. Toxicol Pathol 1984; 12: 3-9.
27. Udall V. Toxicology of sulphonamide-trimethoprim combinations. Postgrad Med J 1969; 45 (suppl): 42-5.
28. Cohen HN, Beastall GH, Ratcliffe WA, et al. Effects on human thyroid function of sulphonamide and trimethoprim combination drugs. Lancet 1980; 281: 646-7.
29. Smellie JM, Bantock HM, Thompson BD. Co-trimoxazole and the thyroid. Lancet 1982; 2: 96.
30. Cohen HN, Pearson DWM, Thomson JA et al. Trimethoprim and thyroid function. Lancet 1981; 1: 676-7.
31. Hall IA, Campbell KL, Chambers MD, et al. Effect of trimethoprim/ sulphamethoxazole on thyroid function in dogs with pyoderma. J Am Vet Med Assoc 1993; 202: 1959-62.
32. Panciera DL, Post K. Effect of oral administration of sulphadiazine and trimethoprim in combination on thyroid function in dogs. Can J Vet Res 1992; 56: 349-52.
33. Post K, Panciera DL, Clark EG. Lack of effect of trimethoprim and sulphadiazine in combination in mid- to late gestation on thyroid function in neonatal dogs. J Reprod Fertil Suppl 1993; 47: 477-82.
34. Angervall L, Bengtsson U, Lehman L. Renal diseases caused by drugs. International Encyclopaedia of Pharmacology and Therapeutics 1972; 75: 243-98.
35. Lehr D. Clinical toxicity of sulfonamides. Ann NY Acad Sci 1957; 69: 417-47.
36. Smith EJ, Light JA, Filo RS, et al. Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. J Am Med Assoc 1980; 44: 360-1.
37. Kraemer MJ, Kendall R, Hickman RO, et al. A generalized allergic reaction with acute interstitial nephritis following trimethoprim-sulfamethoxazole use. Ann Allergy 1982; 49: 323-5.
38. Keitzer WA, Campbell JA. Renal complications of sulfadiazine. JAMA 1942; 119: 701-3.
39. Dorfman LE, Smith JP. Sulfonamide crystalluria: a forgotten disease. J Urol 1970; 104: 482-3.
40. Simon DI, Brosius FC, Rothstein DM. Sulfadiazine crystalluria revisited: the treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med 1990; 150: 2379-84.
41. Abeshouse BS, Tankin LH. Renal complications of sulfonamide therapy. J Urol 1946; 56: 658-7.
42. Buchanan N. Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure. BMJ (1978) 2: 172.
43. Goadsby PJ, Donaghy AJ, Lloyd R. et al. Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure. Ann Int Med 1987; 107: 783-4.
44. Sahai J, Heimberger T, Collins K, et al. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. Am J Med 1988; 84: 791-2.
45. Ventura MG, Wybran J, Farber CM. Sulfadiazine revisited. J Infect Dis 1989; 160: 556-7.
46. Oster S, Hutchison F, McCabe R. Resolution of acute renal failure in toxoplasmic encephalitis despite continuance of sulfadiazine. Rev Infect Dis 1990; 12: 618-20.
47. Farinas MC, Echevarria S, Sampedro I, et al. Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis. J Int Med 1993; 233: 365-7.
48. Maisel B, McSwain B, Glenn F. Effect of administration of sodium sulfadiazine to dogs. Arch Surg 1943; 46: 326-35.
49. Eyangi R, Shigematsu H, Yoshida K, Yoshimuar H. Metabolism and nephrotoxicity of phenacetin and sulfanilamide. J Pharmacobiodyn 1985; 8: 95-105.
50. Murphy FD, Wood WD. Acute nephritis and the effect of sulfonamides on the kidneys. Ann Int Med 1943; 18: 999-1005.
51. Prien EL. The mechanism of renal complications of sulfonamide therapy. N. Engl J Med 1945; 232: 63-8.
52. Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol 1975; 114: 802-8.
53. Shouval D, Ligumsky M, Ben-Ishay D. Effect of co-trimoxazole on normal creatinine clearance. Lancet 1978; 1: 244-5.
54. Aguirre G. Keratoconjunctivitis sicca caused by sulphadiazine. J Am Vet Med Assoc 1973; 162: 8.
55. Slatter DH, Blogg JR. Keratoconjunctivitis sicca in dogs associated with sulphonamide administration. Aust Vet J 1978; 54: 444-6.
56. Berry AP, Startup FG. Possible drug-induced keratoconjunctivitis sicca in a dog. Vet Rec 1985; 117: 367.
57. Collins BK, Moore CP, Hagee JH. Sulphonamide-associated keratoconjunctivitis sicca and corneal ulceration in a dysuric dog. J Am Vet Med Assoc 1986; 189: 924-6.
58. Sutton DJ, Roach NJE. Keratoconjunctivitis sicca associated with potentiated sulphonamides. Vet Rec 1988; 122: 262.
59. Diehl KJ, Roberts SM. Keratoconjunctivitis sicca in dogs associated with sulphonamide therapy: 16 cases (1980-1990). Progress Vet Compr Ophth 1991; 1: 276-82.
60. Morgan RV, Bachrach A. Keratoconjunctivitis sicca associated with sulphonamide therapy in dogs. J Am Vet Med Assoc 1982; 180: 432-4.
61. Sansom J, Barnett KC, Long RD. Keratoconjunctivitis sicca in the dog associated with the administration of salicylazosulphapyridine (sulphasalazine). Vet Rec 1985; 116: 391-3.
62. Berger S, Scagliotti R. A quantitative study of the effects of Tribrissen® on canine tear production. Vet Pathol 1992; 29: 5.
63. Belfort R, de Smet M, Whitcup SM, et al. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with AIDS. Cornea 1991; 10: 536-8.
64. Harle DG, Baldo BA, Wells JV. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol 1988; 25: 1347-54.
65. Carrington DM, Earl HS, Sulivan TJ. Studies of human IgE to a sulfonamide determinant. Allergy Clin Immunol 1987; 79: 442-7.
66. Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulphonamide hypersensitivity reactions by in vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286-9.
67. Koch-Weser J, Sidel VW, Dexter M, et al. Adverse reactions to sulfisoxazole, sulfamethoxazole, and nitrofurantoin. Arch Intern Med 1971; 128: 399-404.
68. Frish JM. Clinical experience with adverse reactions to trimethoprim-sulfamethoxazole. J Infectious Dis 1973; 128: S607-S611.
69. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15438 consecutive inpatients, 1975-1982. J Am Med Assoc 1986; 256: 3358-63.
70. Lang PG. Sulfones and sulfonamides in dermatology today. Am Acad Dermatol 1979; 1: 479-92.
71. Schuppli R. Drug-induced skin reactions. In: Samter M and Parker CW, eds. International encyclopaedia of pharmacology and therapeutics: hypersensitivity to drugs. Pergamon Press Ltd, Oxford, 1972. pp. 205-42.
72. Schulz KH. Cutaneous manifestations of drug allergy. Handbook of Experimental Pharmacology 1983; 63: 135-62.
73. Gruchalla RS, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol 1991; 88: 784-92.
74. Roujeau JC, Stern RS. Severe Adverse Cutaneous Reactions to Drugs. New Eng J Med 1994; 331: 1272-85.
75. Revuz J, Penso D, Roujeau J-C et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-5.
76. Chan H-L, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 1990; 126: 43-7.
77. Hageman PO, Blake FG. A specific febrile reaction to sulfanilamide, drug fever. J Am Med Assoc 1937; 109: 642-6
78. Schlesinger ER, Mitchell WL. Sulfanilamide eruption. Am J Dis Child 1938; 56: 1256-73.
79. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-84.
80. Stürchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous adverse reactions to Fansidar®? Drug Saf 1993; 8: 160-8.
81. Schöpf E. Skin reactions to co-trimoxazole. Infection 1987; 15: S254-S258.
82. Aria J, Fernandes-Rivas, Martinez M, Senent C. Fixed drug eruption caused by sulfaguanidine. Dermatology 1994; 189: 196-7.
83. Oleaga JM, Aguiree A, Gonzalea M, Diaz-Perez JL. Topical provocation of fixed drug eruption due to sulphamethoxazole. Contact Dermatitis 1993; 29: 155.
84. Jim JTE, Chan HL. Fixed drug eruptions due to co-trimoxazole. Ann Acad Med 1992; 21: 408-10.
85. Andersch MA. Hepatic damage associated with sulfonamide therapy in infants and children. Changes in liver function test during sulfonamide therapy. Ann Intern Med 1943; 19: 622-8.
86. Berg PA, Daniel PT. Co-trimoxazole-induced hepatic injury - an analysis of cases with hypersensitivity-like reactions. Infection 1987; 15: S259-S263.
87. Dujovne DA, Chan CH, Zimmerman HJ. Sulfonamide hepatic injury. New Engl J Med 1967; 377: 785-88.
88. Døssing M, Andreasaen PB. Drug-induced liver disease in Denmark. Scand J Gastroenterol 1982; 17: 205-11.
89. Munoz SJ, Martinez-Hernandez A, Maddrey WC. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology 1990; 12: 342-7.
90. Thies PW, Dull WL. Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Arch Intern Med 1984; 144: 1691-2.
91. Steinfort CL, Wiggins J, Sheffield EA, Keal EE. Alveolitis associated with sulphamethoxypyridazine. Thorax 1989; 44: 310-1.
92. Marinac JS. Drug- and chemical-induced aseptic meningitis: a review of the literature. Ann of Pharmacotherapy 1992; 26: 813-22.
93. Joffe AM, Farley JD, Linden D, Goldsand G. Trimethoprim-sulfamethoxazole-associated aseptic meningitis: case reports and review of the literature. Am J Med 1989; 87: 332-8.
94. Blanchard AJ, Mertens GA. Hypersensitivity myocarditis occurring with sulfamethoxypyridine therapy. Can Med Assoc J 1958; 79: 627-30.
95. Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990; 132: 336-42.
96. Platt R, Dreis MW, Kennedy DL, Kuritsky JN. Serum-sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole. J Inf Dis 1988; 158: 474-7.
97. Black-Schaffer B. Pathology of anaphylaxis due to sulfonamide drugs. Arch Pathol 1945; 39: 301-14.
98. Chandra M, Chandra P, McVicar M, et al. Rapid onset of co-trimoxazole induced interstitial nephritis. Int J Ped Nephrol 1985; 6: 289-92.
99. French AJ, Hypersensitivity in the pathogenesis of the histopathologic changes associated with sulfonamide chemotherapy. Am J Pathol 1946; 22: 679-701.
100. Robson M, Levi J, Dolberg L, et al. Acute tubulo-interstitial nephritis following sulfadiazine therapy. Isr J Med Scr 1970; 6: 561-6.
101. Finlayson WB, Johnson G. Multisystem toxicity after co-trimoxazole. Lancet 1978; 2: 682-3.
102. Richmond JM, Whitworth JA, Fairley KF, et al. Co-trimoxazole nephrotoxicity. Lancet 1979; 1: 493.
103. Gupta A, Eggo MC, Uetrecht JP, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulphonamides. Clin Pharmacol Ther 1992; 51: 56-67.
104. Keisu M, Ekman E, Wiholm B-E. Comparing risk estimates of sulphonamide-induced agranulocytosis from the Swedish Drug Monitoring System and a case-control study. Eur J Clin Pharmacol 1992; 43: 211-4.
105. Hopkinson ND, Garcia FS, Gumpel JM. Haematological side-effects of sulphasalazine in inflammatory arthritis. Br J Rheumatol 1989; 36: 4013-5.
106. Beutler E. Glucose-6-phosphate dehydrogenase deficiency. N. Eng J Med 1991; 324: 169-74.
107. Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Reviews of Infectious Diseases 1987; 9: S218-S229.
108. Boussemart T, Nasimi A, Mulot F et al. Déficit en G6PD révélé par une consommation de fèves et al prise de sulfaméthoxazole. La presse médicale 1995; 24: 960.
109. Tilden ME, Rosenbaum JT, Fraunfelder FT. Systemic sulfonamides as a cause of bilateral, anterior uveitis. Arch Ophthalmol 1991; 109: 67-9.
110. Schneider MME, Nielsen TL, Nelsing S et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. J Infect Dis 1995; 171: 1632-6.
111. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiences. Ann Intern Med 1984; 100: 663-71.
112. Jaffe HS, Ammann AJ, Abrams DI, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; ii: 109.
113. Mitsuyasu R, Groopman J, Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. N Engl J Med 1983; 308: 1535-6.
114. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323: 776-82.
115. Roudier C, Caumes E, Rogeaux O, Bricaise F, Gentilinie M. Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Arch Dermatol 1994; 130: 1383-6.
116. Caumes E, Roudier C, Rogeaux O et al. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated Pneumocystis carinii pneumonia. Clinical Infectious Diseases 1994; 18: 319-23.
117. Gibbon RB, Lindauer JA. Successful treatment of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in hypersensitive AIDS patients. J Amer Med Assoc 1985; 253: 1259.
118. Shafer RW, Seitzman PA, Tapper ML. Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions. J Acq Immun Defic Syn 1989; 2: 389.
119. Jung AC, Paauw DS. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 1994; 15: 2402-06.
120. Correia O, Chosidow O, Saiage P et al. Evolving patterns of drug-induced toxic epidermal necrolysis. Dermatology 1993; 186: 32-7.
121. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acq Immun Defic Synd 1992; 5: 1237-57.
122. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. Acq Immun Def Syn 1993; 7: 65-71.
123. Kelly JW, Dooley DP, Lattuada CP, Smith CE. A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus. J Infect Dis 1992; 14: 1034.
124. Cribb AE. Idiosyncratic reactions to sulphonamides in dogs. J Am Vet Med Assoc 1989; 195: 1612-4.
125. Giger U, Werner LL, Millichamp NJ, et al. Sulphadiazine-induced allergy in six Doberman Pinschers. J Am Vet Med Assoc 1985; 186: 479-84.
126. Werner LL, Bright JM. Drug-induced hypersensitivity disorders in two dogs treated with trimethoprim sulphadiazine: case reports and drug challenge studies. J Am Anim Hosp Assoc 1983; 19: 783-90.
127. Lees GE, Rogers KS, Troy GC. Polyarthritis associated with sulphadiazine administration in a Labrador retriever dog. Southwest Vet 1986; 37: 13-7.
128. Harvey RG. Possible sulphadiazine-trimethoprim induced polyarthritis. Vet Rec 1987; 120: 537-8.
129. Grondalen J. Trimethoprim-sulphonamide induced polyarthritis. Vet Rec 1987; 121: 155.
130. Gray A. Trimethoprim-sulphonamide hypersensitivity in dogs. Vet Rec 1990; 127; 579-80.
131. Kunkle GA, Sundlof S, Keisling K. Adverse side effects of oral antibacterial therapy in dogs and cats: an epidemiologic study of pet owners' observations. J Am Anim Hosp Assoc 1995; 31: 46-55.
132. Little CJL, Carmichael S. Trimethoprim-sulphonamide hypersensitivity in dogs. Vet Rec 1990; 127: 459-60.
133. Wuhr P. Possible trimethoprim-sulphonamide induced polyarthritis. Vet Rec 1987; 120: 291.
134. Weiss DJ, Adams LG. Aplastic anemia associated with trimethoprim/sulphadiazine and fenbendazole administration in a dog. J Am Vet Med Assoc 1987; 191: 1119-20.
135. Fox LE, Ford S, Alleman AR, et al. Aplastic anemia associated with prolonged high-dose trimethoprim-sulphadiazine administration in two dogs. Vet Clin Pathol 1993; 22: 89-92.
136. Sullivan PS, Arrington K, West R, et al. Thrombocytopenia associated with administration of trimethoprim/sulphadiazine in a dog. J Am Vet Med Assoc 1992; 201: 1741-44.
137. Trepanier LA. Unpublished observations, 1995.
138. Toth DM, Derwelis SK. Drug-induced hepatitis in a dog. Vet Med/SAC 1980; 75: 421-2.
139. Thornburg LP. A study of canine hepatobiliary disease, Part 5: drug-induced hepatopathies. Compan Anim Pract 1988; 2: 17-21.
140. Anderson WI, Campbell KL, Wilson RC, et al. Hepatitis in a dog given sulphadiazine-trimethoprim and cyclophosphamide. Mod Vet Pract 1984; 65: 115.
141. Bunch SE. Hepatotoxicity associated with pharmacologic agents in dogs and cats. Vet Clin North Am Small Anim Pract 1993; 23: 659-70.
142. Thomson GW. Possible sulphamethoxazole/trimethoprim-induced hepatic necrosis in a dog. Can Vet J 1990; 31: 530.
143. Rowland PH, Center SA, Dougherty SA. Presumptive trimethoprim-sulphadiazine-related hepatotoxicosis in a dog. J Amer Vet Med Assoc 1992; 200: 348-51.
144. Scott DW, Barrett RE, Tangorra L. Drug eruption associated with sulphonamide treatment of vertebral osteomyelitis in a dog. J Am Vet Med Assoc 1976; 168: 111-4.
145. Scott DW, Smith FWK, Smith CA. Erythema multiforme and pemphigus-like antibodies associated with sulphamethoxazole-trimethoprim administration in dogs with polycystic kidneys. Can Pract 1986; 13: 35-8.
146. Scott DW, Miller WH, Griffin CE. Muller & Kirk's Small Animal Dermatology, 5th ed. Philadelphia: W.B. Saunders, 1995; pp. 590-5.
147. Medleau L, Shanley KJ, Rakich PM et al. Trimethoprim-sulphonamide-associated drug eruptions in dogs. J Am Anim Hosp Assoc 1990; 26: 305-11.
148. Lindgren A, Olsson R. Liver reactions from trimethoprim. J Intern Med 1994; 236: 281-4.
149. Greenberg S, Reiser IW, Chou SY. Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy. Am J Kidney Dis 1993; 22: 603-6.
150. Noto H, Kaneko Y, Takano T, Kurokawa K. Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carnii pneumonia. Internal Medicine 1995; 34: 96-7.
151. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119: 296-301.
152. Brumfitt W, Hamilton-Miller JMT. Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. J Chemotherapy 1993; 5: 465-69.
153. Brumfitt W, Hamilton-Miller JMT. Limitations of and indications for the use of cotrimoxazole. J Chemotherapy 1994; 6: 3-11.
154. Brumfitt W, Hamilton-Miller JMT. Combinations of sulphonamides with diaminopyrimidines: how, when and why? J Chemotherapy 1995; 7: 136-9.
155. Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 1995; 15: 428-32.
156. Vree TB, Hekster YA. Pharmacokinetics of sulfonamides revisited. Antibiot Chemother 1985; 35: 1-177
157. Vree TB, Hekster YA. Clinical pharmacokinetics of sulfonamides and their metabolites. Antibiot Chemother 1987; 37: 1-214.
158. Vree TB, van der Ven AJAM, Koopsman PP et al. Pharmacokinetics of sulfamethoxazole with its hydroxy metabolites and N4-acetyl-, N1-glucuronide conjugates in healthy human volunteers. Clin Drug Invest 1995; 9: 43-53.
159. Cribb AE, Speilberg SP. Sulphamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522-6.
160. van der Ven AJAM, Mantel MA, Vree TB, Koopmans PP, van der Meer JWM. Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole. Br J Clin Pharmacol 1994; 38: 147-50.
161. Stevens RC, Laizure SC, Sanders PL, Stein DS. Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Antimicrob Agents Chemother 1993; 37: 448-52.
162. Lee BL, Medina I, Benowitz NL, Jacob P. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia inpatients with the acquired immunodeficiency syndrome. Evidence of drug interactions. Ann Intern Med 1989; 100: 606-11.
163. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver enzymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39: 184-91.
164. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol 1992; 45: 1277-82.
165. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989; 34: 1989.
166. 4-hydroxylation of sulfamethoxazole by cytochrome P450 of the CYP2C subfamily and microsomal reduction of its hydroxylamine metabolite in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23: 406-14.
167. Cribb AE, Miller M, Tesoro A, Spielberg SP. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol Pharmacol 1990; 38: 744-51.
168. Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Drug Metab Disp 1991; 19: 900-6.
169. Nakamura H, Uetrecht J, Cribb AE, Miller MA, Zahid N, Hill J, Josephy PD, Grant DM, Spielberg SP. Formation and disposition of N-acetoxy sulfamethoxazole in vitro. J Pharmacol Exp Ther 1995; in press.
170. Kiese M. The biochemical production of ferrihemoglobin-forming derivatives from aromatic amines and mechanisms of ferrihemoglobin formation. Pharmacol Rev 1966; 18: 1091-161.
171. 4-hydroxylase activity in kidney and liver microsomes of rats by pre-treatment with 3-methylcholanthrene type-polychlorinated biphenyl. J Pharm Dyn 1982; 5: 853-8.
172. Woolhouse NM, Atu-Taylor LC. Influence of double genetic polymorphism on response to sulfamethazine. Clin Pharmacol Ther 1982; 31: 377-83.
173. Rieder MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulphonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13-7.
174. Wolkenstein P, Charue D, Laurent P et al. Metabolic predisposition to cutaneous adverse drug reactions. Arch Dermatol 1995; 131: 544-51.
175. van der Ven AHAM, Vree TB, et al. Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br J Clin Pharmac 1995; 39: 621-25.
176. Cribb AE, Nuss CE, Alberts DW, Lamphere DB, Grant DM, Grossman SJ, and Spielberg SP. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 1995; submitted.
177. Shear NH, Spielberg SP. In vitro evaluation of a toxic metabolite of sulphadiazine. Can J Physiol Pharmacol 1985; 63: 1370-2.
178. Riley RJ, Cribb AE, Spielberg SP. Glutathione transferase μ deficiency is not a marker for predisposition to sulphonamide toxicity. Biochem Pharamcol 1991; 42: 696-8.
179. Pickett CB, Belsha CW, Kearns GL. Multi-organ disease secondary to sulfonamide toxicity. Pediatrics 1994; 94: 237-9.
180. Cribb AE, Spielberg SP. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Disp 1990; 18: 784-7.
181. Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulphonamides. J Pharmacol Exp Ther 1988; 244: 724-8.
182. Spielberg SP, Leeder JS, Cribb AE, and Dosch H-M. Is sulfamethoxazole hydroxylamine the proximal toxin in sulfaemethoxazole toxicity? Eur J Clin Pharm 1989; 36(supp): A146.
183. Spielberg SP. Pathogenesis and pharmacogenetics of idiosyncratic hypersensitivity adverse drug reactions. In Idiosyncratic Adverse Drug Reactions. Naranjo CA, Jones JK, eds. 1990; pp 145-58 Elsevier Science Publishers B.V.
184. Cribb AE, Spielberg SP. An in vitro investigation of predisposition to sulfonamide idiosyncratic toxicity in dogs. Vet Res Commun 1990; 14: 241-52.
185. Rieder MJ, Krause R, Bird IA, Dekaban GA. Toxicity of sulfonamide reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells. J Acquir Immune Defic Syndr Hum Retrovirology 1995; 8: 134-40.
186. Cribb AE. Unpublished observations. 1995.
187. Cribb AE, Grant DM, Miller M, and Spielberg SP. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocyes. J Pharmacol Exp Ther 1991; 251: 1241-7.
188. Spielberg SP, Nuss C, Cribb AE. Formation and disposition of sulfamethoxazole hydroxylamine. Clin Pharmacol Ther 1995; 57: 221.
189. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529-35.
190. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 1994; 8: 333-7.
191. Deloménie C, Grant DM, Mathelier-Fusade P et al. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharamcol 1994; 38: 581-2.
192. Lee BL, Delahunty T, Safrin S. The hydroxylamine of sulfamethoxazole and adverse reactions in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1994; 56: 184-9.
193. Chin TWF, Vandenbroucke A, Fong IW. Pharmacokinetics of trirnethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995; 39: 28-33.
194. Uetrecht JP. Mechanism of drug-induced lupus. Chem Res Toxicol 1988; 1: 133-43.
195. Carr A, Tindall B, Penny R, Cooper DA. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993; 94: 21-5.
196. Buhl R, Jaffe HA, Holroyd KJ et al. Systemic glutathione deficiency in symptomfree HIV-seropositive individuals. Lancet 1989; 2: 1294-8.
197. Aukrust P, Svardal AM, Müller F et al. Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1c infections. Blood 1995; 86: 258-67.
198. Riley RJ, Spieiberg SP, Leeder JS. A comparative study of the toxicity of chemically reactive xenobiotics towards adherent cell cultures: a selective attenuation of menadione toxicity by buthionine sulphoximine pretreatment. J Pharm Pharmacol 1993; 45: 263-7.
199. Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987; 36: 581-90.
200. Parker CW. Allergic reactions in man. Pharmacol Rev 1982; 34: 84-104.
201. Macy EM. Current sulfamethoxazole skin test reagents fail to predict recurrent adverse reactions. J Allergy Clin Immunol 1995; 95: 171.
202. Daftarian MP, Filion LG, Cameron W et al. Immune response to sulfamethoxazole in patients with AIDS. Clin Diagn Lab Immunol 1995; 2: 199-204.
203. O'Neil CB, Reed MA, Lopez M, Hyslop N, Gutierrez E, Salvaggio J. Evaluation of immune parameters in HIV+ subjects reporting adverse reactions to sulfamethoxazole. Int Arch Allergy Appl Immunol 1991; 94: 246-7.
204. Curtis BR, McFarland JG, Wu G-G, Visentin GP, Aster RH. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994; 84: 176-83.
205. Kiefel V, Santosa S, Schmidt S, Salama A, Mueller-Eckhardt C. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia. Transfusion 1987; 27: 262-5.
206. Daniel PT, Holzschuh J, Berg PA. Sulfadoxine specific lymphocyte transformation in a patient with eosinophilic pneumonia induced by sulfadoxine-pyrmethamine (Fansidar). Thorax 1989; 44: 307-9.
207. Hofer T, Becker EW, Weigand K, Berg PA. Demonstration of sensitized
208. Kalish RS, LaPorte A, Wolod JA, Johnson KL. Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions. J Allergy Clin Immunol 1994; 94: 465-72.
209. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug specific CD4 + and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155: 462-72.
210. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP, Homberg JC. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551-5.
211. Leeder JS, Rile R, Cook VA, Spielberg SO. Human Anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther 1992; 263: 360-7.
212. Kenna JG, Satoh H, Christ DD, Pohl LR. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988; 245: 1103-9.
213. Bray VJ, West SG, Schultz KT, Boumpas DT, Rubin RL. Antihistone antibody profile in sulfasalazine induced lupus. J Rheuma toi 1994; 21: 2157-8.
214. Caulier M, Dromer C, Andrieu V, Le Guennec P, Fournie B. Sulfasalazine induced lupus in rheumatoid arthritis. J Rheumatol 1994; 21: 750-1.
215. Fraunfelder FT, Meyer SM, Bagby GC, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol 1985; 100: 79-81.
216. Keishu M, Wilhom BE, Ost A, Mortimer O. Acetazolimide-associated aplastic anemia. J Intern Med 1990; 228: 627-32.
217. Bretza JA. Thrombocytopenia due to sulfonamide cross-sensitivity. Wisconsin Med J 1982; 81: 21-3.
218. Hansborough JR, Wedner J, Chaplin DD. Anaphylaxis to intravenous furosemide. J Allergy Clin Immunol 1987; 80: 538-41.
219. McCall C, Ohnemus C, Gallegos A, Kehl J, McLeod D. Determination of cross reactivity of IgG antibodies raised against sulfamethoxazole (SMX) with other sulfonamides. J Allergy Clin Immunol 1995; 95: 286.